Recalls / Class II
Class IID-0559-2020
Product
fentaNYL 200 mcg/100 mL (2 mcg/mL) BUPivacaine HCl 0.1% 100 mg/100 mL (1 mg/mL) in 0.9% Sodium Chloride 100 mL CADD Preservative Free, Rx, QuVA Pharma 1075 West Park One Drive, Suite 100 Sugar Land, TX 77478 NDC 70092-1255-75
- Affected lot / code info
- Lots: 10029914 Exp. 11/20/2019, 10030342 Exp. 11/24/2019, 10030948 Exp. 12/3/2019, 10030895 Exp. 12/2/2019, 10030949 Exp. 12/3/2019, 10030895 Exp. 12/2/2019, 10031377 Exp. 12/6/2019, 10031141 Exp. 12/9/2019, 10031423 Exp. 12/15/2019, 10031627 Exp. 12/19/2019, 10031709 Exp. 12/22/2019, 10031907 Exp. 12/25/2019, 10032022 Exp. 12/27/2019, 10031858 Exp. 12/24/2019, 10032381 Exp. 1/1/2020, 10032296 Exp. 12/31/2019, 10032268 Exp. 12/30/2019, 10032467 Exp. 1/2/2020, 10032674 Exp. 1/8/2020, 10032569 Exp. 1/6/2020, 10032570 Exp. 1/6/2020, 10032516 Exp. 1/5/2020, 10032517 Exp. 1/5/2020, 10032674 Exp. 1/8/2020, 10032570 Exp. 1/6/2020, 10032675 Exp. 1/8/2020, 10033019 Exp. 1/15/2020,
Why it was recalled
Presence of Particulate matter: manufacturer recalled fentanyl API due to potential for glass particules
Recalling firm
- Firm
- QuVa Pharma, Inc.
- Notification channel
- Letter
- Type
- Voluntary: Firm initiated
- Address
- 1075 W Park One Dr Ste 100, Sugar Land, Texas 77478-2576
Distribution
- Distribution pattern
- Nationwide.
Timeline
- Recall initiated
- 2019-11-12
- FDA classified
- 2019-12-03
- Posted by FDA
- 2019-12-11
- Terminated
- 2020-06-05
- Status
- Terminated
Source: openFDA Drug Enforcement endpoint. Recall record D-0559-2020. The FDA issues recall classifications as health-hazard assessments, not legal findings; for legal claims consult a licensed attorney.